Premium
Abstracts of the 110th meeting of the British Neuropathological Society
Author(s) -
Mackenzie, S. C.,
Janczar, K.,
Croisier, E.,
Brock, C.,
von Holt, S. J. Davidson,
Turkheimer, Federico,
Roncaroli, F.
Publication year - 2009
Publication title -
neuropathology and applied neurobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.538
H-Index - 95
eISSN - 1365-2990
pISSN - 0305-1846
DOI - 10.1111/j.1365-2990.2008.01003.x
Subject(s) - medicine
Several clinical trials have demonstrated that expression of O6methylguanine-DNA methyltransferase (MGMT) is an independent prognostic factor in predicting the response to alkylating agents in patients with high grade astrocytoma1-2. However, the current methods to evaluate MGMT expression immunohistochemistry and methylation-specific PCR may show discordant results and thus hamper reliable stratification of patients. Inconsistencies in the results have been attributed to MGMT expression in the nonneoplastic cell component of tumours which includes lymphocytes, vascular endothelial cells, and macrophages/microglia3.